Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.
Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.
A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.